Bookmark and Share
Feed icon


chromosome 22q deletion

Parkinson's chromosome deletion linked to other genetic disorders

Researchers, led by BRC-supported Professor Nicholas Wood, UCL Institute of Neurology, have made a breakthrough in their understanding of Parkinson’s disease after they discovered a chromosome deletion linked to Parkinson’s disease and other genetic disorders. More...

Prof John Hardy

Prof John Hardy is the first UK winner of $3m Breakthrough Prize in Life Sciences

Professor John Hardy (UCL Institute of Neurology) has been awarded the $3 million Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. More...

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.

Video: Parkinson's UK site visit for the Targeting LRRK2 project

1 November 2011

LRRK2 from Tony Cox on Vimeo.

LRRK2 – pronounced lark 2 – is the most common gene associated with Parkinson’s. A mutant form of LRRK2 can cause the death of nerve cells, and blocking this form of LRRK2 from working can prevent this from happening. Before we can use this knowledge to develop treatments we need to fill in the gaps in our understanding of the role LRRK2 plays when it’s healthy, and of the different proteins it interacts with along the way within the nerve cell.

Figuring out how LRRK2 works and how to change this is a promising route to developing novel therapies for the treatment and ultimately cure for Parkinson’s. Although a long way off, we hope that these can ultimately be tested in the clinic to see if we can slow down or alter the progress of the condition.

Patrick Lewis - Lead researcher for the Targeting LRRK2 project

Patrick Lewis' profile

More information (PDF) on the Targeting LRRK2 project

Page last modified on 01 nov 11 14:21